MAPS EMEA 2025

Amplifying the Patient Voice: Reflections from MAPS EMEA 2025

At this year’s MAPS EMEA 2025 Annual Meeting in London, the message was clear: the patient voice is central to every stage of the drug development journey, a theme eloquently showcased in the Opening General Assembly: Patient Impact on Medical Affairs. Global leaders in Medical Affairs gathered to explore how the industry can evolve from…...
Read More

Top Stories

NASSCOM GCC Summit 2025

What’s Next for Global Capability Centers )?

The theme for this year’s NASSCOM GCC Summit, “The Next GCC...
MAPS 2025

MAPS 2025 Decoded: The Medical Affairs Playbook

At the MAPS Americas 2025 conference in New Orleans, one of...
DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for

Digital and AI were hot topics underpinning many of the...
MAPS EMEA 2025

Amplifying the Patient Voice: Reflections from MAPS EMEA 2025

At this year’s MAPS EMEA 2025 Annual Meeting in London, the message was clear: the...
Global Capability Centers

Unlocking the Power of Global Capability Centers (GCCs) in Biopharma: Drive Efficiency, Innovation, and Scientific Excellence

As global biopharma companies face rising demands for efficiency, standardization, and scientific excellence, Global Capability...
MAPS 2025

MAPS 2025 Decoded: The Medical Affairs Playbook for Successful Drug Launches

At the MAPS Americas 2025 conference in New Orleans, one of the pivotal discussions centered...
DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for Change in Writing, MedComms, and Field Strategy

Digital and AI were hot topics underpinning many of the conversations at the DIA’s Medical...

Medical Information in the Digital Age – Quick and Efficient Meets Responsive and Responsible

Medical Information (MI teams across the pharmaceutical industry respond to product-related medical queries from HCPs...
Stakeholder perspectives on digital scientific content

Digital Scientific Content: Stakeholder Perspectives

What do the different relevant stakeholder groups truly expect from pharma-generated scientific content?...

Learn more ABOUT our company.